EVOK NASDAQ
Solana Beach, CA 92075
US
Evoke Pharma, Inc. operates as a specialized pharmaceutical entity, primarily focused on inventing and bringing to market therapeutic agents for various digestive system illnesses. The company's lead development candidate is Gimoti, a metoclopramide nasal spray, which has progressed through and completed its Phase 3 clinical trials. This medicine is being developed to mitigate symptoms associated with both acute and recurring diabetic gastroparesis, specifically in female patients. Evoke Pharma distributes its offerings to a broad base of healthcare professionals, encompassing digestive disease specialists, internists, general practitioners, and certain other medical providers. Established in 2007, the company's corporate offices are situated in Solana Beach, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Nantahala Capital Ma | J-Other | 148,153 | $11.00 | 2025-12-17 |
| Nantahala Capital Ma | J-Other | 117,019 | $8.16 | 2025-12-17 |
| Nantahala Capital Ma | J-Other | 117,019 | $8.16 | 2025-12-17 |
| PYSZCZYMUKA GREG | D-Return | 5,833 | $5.26 | 2025-12-17 |
| PYSZCZYMUKA GREG | D-Return | 1,155 | $3.45 | 2025-12-17 |